We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+23.47%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.49B
AUM Growth
+$497M
Cap. Flow
+$426M
Cap. Flow %
12.21%
Top 10 Hldgs %
38.36%
Holding
80
New
20
Increased
14
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$161M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$139M
3
APLS
Apellis Pharmaceuticals
APLS
+$63.7M
4
DYN icon
Dyne Therapeutics
DYN
+$57.8M
5
NTLA icon
Intellia Therapeutics
NTLA
+$54.5M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$52.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48.2M
3
RAPT
RAPT Therapeutics
RAPT
+$44.6M
4
ACLX
Arcellx
ACLX
+$40.2M
5
ANAB icon
AnaptysBio
ANAB
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
76
Protagonist Therapeutics
PTGX
$9.3B
– –
-275,201
Closed -$6.31M
RAPT
77
DELISTED
RAPT Therapeutics
RAPT
– –
-224,246
Closed -$44.6M
SRPT icon
78
Sarepta Therapeutics
SRPT
$2.13B
– –
-500,000
Closed -$48.2M
AMAM
79
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-3,710,412
Closed -$52.8M
ORTX
80
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-2,041,670
Closed -$33.6M
1 2 3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Deep Track Capital held 80 positions worth $3.49B, up 17% from $2.99B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deep Track Capital deployed $426M of net new capital in Q1 2024, opening 20 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 550,000 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AnaptysBio, an estimated $35.7M trimmed.

  • Deep Track Capital's largest Q1 2024 buy was Amgen: 550,000 shares worth $156M.
  • Deep Track Capital added most to Dyne Therapeutics in Q1 2024, an estimated $57.8M increase.
  • Deep Track Capital's biggest Q1 2024 reduction was AnaptysBio, cutting an estimated $35.7M.
  • Deep Track Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $52.8M.
  • Deep Track Capital's ten largest holdings make up 38% of its $3.49B portfolio in Q1 2024.
  • Deep Track Capital opened 20 new positions and closed 14 in Q1 2024.
  • Deep Track Capital's portfolio value rose 17% quarter-over-quarter to $3.49B.

Based on Deep Track Capital's 13F filing for Q1 2024, filed 15 May 2024.